Riskpilot← Back to searchSign inGet full accessNORDICCELL ApS
APSActiveCVR 27293972Fruebjergvej 3Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200313 employees
Revenue 2025
DKK 8,9M
+7% vs 2024
EBITDA margin
33.8%
+26% vs 2024
Equity ratio
35.8%
Financial strength
Net profit 2025
DKK 1,7M
+34% vs 2024
| Revenue | DKK 8,9M | +7% |
| EBITDA | DKK 3M | +26% |
| Net profit | DKK 1,7M | +34% |
| Total assets | DKK 13,9M | +14% |
| Equity | DKK 5M | +0% |
| Employees | 13 | — |
Legal name
NORDICCELL ApS
CVR number
27293972
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
12. august 2003
Share capital
DKK 125.000
Employees
13 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen eller den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed inden for distribution af engangsartikler, laboratorieudstyr, forskningsredskaber samt anden dermed beslægtet virksomhed.
Address
Fruebjergvej 3
Phone
+4570251535
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.428 | 2.739 | 3.833 | 4.794 | 5.579 | 7.136 | 6.545 | 6.803 | 8.599 | 10.834 | 12.989 | 11.845 | 8.347 | 8.909 |
| Staff expenses | -1.804 | -1.924 | -2.414 | -2.882 | -3.099 | -3.965 | -4.568 | -5.323 | -4.733 | -5.838 | -6.870 | -6.647 | -5.965 | -5.806 |
| EBITDA | 624 | 815 | 1.418 | 1.913 | 2.480 | 3.171 | 1.977 | 1.481 | 3.865 | 4.996 | 6.118 | 5.198 | 2.381 | 3.010 |
| Depreciation & amort. | -74 | -59 | -9 | -8 | -15 | -35 | -40 | -49 | -110 | -56 | -620 | -620 | -636 | -677 |
| EBIT | 550 | 756 | 1.410 | 1.905 | 2.465 | 3.136 | 1.937 | 1.431 | 3.755 | 4.940 | 5.498 | 4.578 | 1.746 | 2.332 |
| Net financials | -192 | -25 | 205 | 124 | 128 | 222 | 5 | -283 | 29 | -140 | -81 | 15 | -112 | -146 |
| Profit before tax | 358 | 731 | 1.614 | 2.029 | 2.593 | 3.358 | 1.942 | 1.149 | 3.784 | 4.800 | 5.417 | 4.592 | 1.634 | 2.186 |
| Tax | 93 | 185 | 400 | 485 | 574 | 742 | 429 | 262 | 836 | 1.057 | 1.193 | 1.017 | 361 | 485 |
| Net profit | 265 | 546 | 1.214 | 1.543 | 2.019 | 2.616 | 1.513 | 886 | 2.947 | 3.744 | 4.224 | 3.576 | 1.273 | 1.701 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3.488 | 3.468 | 5.259 | 5.145 | 6.492 | 7.257 | 9.473 | 10.167 | 11.663 | 14.512 | 13.877 | 17.617 | 12.163 | 13.914 |
| Equity | 1.021 | 1.067 | 1.281 | 1.325 | 1.344 | 3.960 | 2.873 | 2.259 | 4.327 | 7.302 | 7.826 | 7.202 | 4.975 | 4.976 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 233 | 0 | 696 | 1.059 | 1.317 | 1.223 | 410 | 604 |
| Short-term debt | 2.467 | 2.401 | 3.978 | 3.820 | 5.148 | 3.296 | 6.175 | 7.435 | 6.029 | 5.542 | 4.250 | 8.915 | 6.551 | 8.229 |
| Total debt | 2.467 | 2.401 | 3.978 | 3.820 | 5.148 | 3.296 | 6.408 | 7.435 | 6.725 | 6.601 | 5.567 | 10.138 | 6.961 | 8.833 |
EBITDA margin
33.8%
This company
15.8%
Market median
+114% vs market
20122025
Equity ratio
35.8%
This company
38.2%
Market median
+6% vs market
20122025
Return on equity
34.2%
This company
18.4%
Market median
+86% vs market
20122025
Net profit margin
19.1%
This company
8.1%
Market median
+136% vs market
20122025
Asset turnover
0.64×
This company
1.12×
Market median
-43% vs market
20122025
Debt / equity
1.80×
This company
0.62×
Market median
-190% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AB Chief Executive Officer | Chief Executive Officer | 2003 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BEK-PEDERSEN HOLDING ApS | Company | 100.0% | 100.0% | 2003 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BEK-PEDERSEN HOLDING ApS
NORDICCELL ApS Board members of NORDICCELL ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Bek-Pedersen | Chief Executive Officer | 0 companies |